CFDA

PAREXEL adds senior executives from FDA and oncology industry

Wednesday, November 15, 2017

PAREXEL, a global biopharmaceutical services provider, announced the appointment of three former senior regulatory consulting executives from the FDA and Oncology industry positions. The new hires are part of PAREXEL’s Global Integrated Product Development and Compliance team and will be focused on helping PAREXEL clients deliver commercially viable, reimbursable products to market faster and more cost-effectively.

[Read More]

Certara launches Simcyp Access to expand simulator availability

Thursday, March 9, 2017

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has announced the launch of Simcyp Access. This new cloud-based licensing approach provides trained individuals at smaller pharmaceutical companies (less than 500 employees) with a method for using Certara’s Simcyp Population-based Simulator in research projects. 

[Read More]

Horizon Discovery enters Chinese Clinical Diagnostics Market

Monday, November 21, 2016

Horizon Discovery Group, a leader in the application of gene editing technologies, has entered into partnerships with three leading Chinese diagnostic kit developers. Under the terms of the agreements, Horizon will provide HDx Reference Standards for novel Next Generation Sequencing (NGS) assay development, clinical trials, and ultimately for inclusion as in-kit controls under Original Equipment Manufacturer (OEM) agreements.

[Read More]

Huawei, WuXi AppTec partner on China Precision Medicine Cloud Platform

Thursday, March 17, 2016

Huawei, a global information and communications technology provider, and WuXi AppTec, a global open-access R&D platform, have announced the signing of a strategic framework agreement to support the China Precision Medicine Initiative (China PMI) through the creation of a state-of the-art precision medicine cloud platform. The agreement builds on Huawei’s capabilities and reach in cloud infrastructure, and the genomics and precision medicine expertise of WuXi NextCODE, the global genomic information and precision medicine subsidiary of WuXi AppTec.

[Read More]

Certara launches a consulting company in China

Tuesday, January 12, 2016

Certara, a global biosimulation technology-enabled drug development company, has launched Certara Strategic Consulting China in Shanghai. This new company is being led by President and CEO Christine Yuying Gao, M.D., Ph.D., former vice president of consulting services at Quantitative Solutions, a global pharmacometrics consulting company. Quantitative Solutions merged with Certara’s Pharsight Consulting Services in July 2015 to form Certara Strategic Consulting.

[Read More]